{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T03:42:57Z","timestamp":1774410177748,"version":"3.50.1"},"reference-count":31,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"unspecified","delay-in-days":27,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2022,8,29]]},"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec>\n                  <jats:title>Background\/objective<\/jats:title>\n                  <jats:p>The aim of this study was to evaluate relative performance of composite measures in psoriatic arthritis and assess the impact of structural damage and functional disability on outcomes during ixekizumab treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data from SPIRIT-P1 and SPIRIT-P2 were analysed to evaluate the effect of ixekizumab on achievement of low disease activity (LDA) and remission with the minimal disease activity (MDA) and very low disease activity (VLDA) composite, Disease Activity index for Psoriatic Arthritis (DAPSA), Psoriatic Arthritis Disease Activity Score, GRAppa Composite ScorE and modified Composite Psoriatic Disease Activity Index (mCPDAI). Performance was compared by quantifying residual symptom burden and the impact of structural damage and functional disability.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Significantly more ixekizumab-treated patients achieved treatment targets at week 24 versus placebo assessed with all composites. More patients achieved targets assessed by mCPDAI and DAPSA than other composites. Residual disease activity was similar between composites, but residual high patient-reported outcomes (PROs) and functional disability were more frequent when assessed with mCPDAI and DAPSA. Achievement of treatment targets was reduced by high baseline levels of structural damage and functional disability.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Residual disease activity was similar in patients achieving treatment targets assessed with all composites, but residual high PROs and functional disability were more common when assessed with mCPDAI and DAPSA, most likely due to the absence\/attenuated functional assessment in these composites. High baseline levels of structural damage and functional disability attenuated response rates with all composites, affecting MDA\/VLDA most prominently; LDA may be the most appropriate target in these patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01695239\">NCT01695239<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2022-002457","type":"journal-article","created":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T11:25:57Z","timestamp":1664364357000},"page":"e002457","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct01695239","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01695239","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02349295","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4756-663X","authenticated-orcid":false,"given":"Laura C","family":"Coates","sequence":"first","affiliation":[{"name":"Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josef S","family":"Smolen","sequence":"additional","affiliation":[{"name":"Medical University of Vienna, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J","family":"Mease","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Swedish Medical Center, Providence St Joseph Health, and School of Medicine, University of Washington, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Elaine","family":"Husni","sequence":"additional","affiliation":[{"name":"Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Lespessailles","sequence":"additional","affiliation":[{"name":"University of Orleans, Orleans Hospital, Orleans, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4007-1589","authenticated-orcid":false,"given":"Mitsumasa","family":"Kishimoto","sequence":"additional","affiliation":[{"name":"School of Medicine, Kyorin University, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Macpherson","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J","family":"Bradley","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Bolce","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4155-9105","authenticated-orcid":false,"given":"Philip S.","family":"Helliwell","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Leeds, Leeds, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,9,28]]},"reference":[{"key":"2025090312540292000_8.2.e002457.1","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025090312540292000_8.2.e002457.2","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.semarthrit.2020.03.015","article-title":"Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study","volume":"50","author":"Coates","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2025090312540292000_8.2.e002457.3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/acr.23789","article-title":"2018 American College of Rheumatology\/National psoriasis Foundation guideline for the treatment of psoriatic arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Care Res"},{"key":"2025090312540292000_8.2.e002457.4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211734"},{"key":"2025090312540292000_8.2.e002457.5","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.135087"},{"key":"2025090312540292000_8.2.e002457.6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211433"},{"key":"2025090312540292000_8.2.e002457.7","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.102053"},{"key":"2025090312540292000_8.2.e002457.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201341"},{"key":"2025090312540292000_8.2.e002457.9","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.129379"},{"key":"2025090312540292000_8.2.e002457.10","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.117945"},{"key":"2025090312540292000_8.2.e002457.11","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.190867"},{"key":"2025090312540292000_8.2.e002457.12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-216999"},{"key":"2025090312540292000_8.2.e002457.13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207507"},{"key":"2025090312540292000_8.2.e002457.14","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.berh.2018.08.004","article-title":"Disease activity assessment in patients with psoriatic arthritis","volume":"32","author":"Kerschbaumer","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2025090312540292000_8.2.e002457.15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209709"},{"key":"2025090312540292000_8.2.e002457.16","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170429"},{"key":"2025090312540292000_8.2.e002457.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31429-0"},{"key":"2025090312540292000_8.2.e002457.18","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/rheumatology\/key182","article-title":"Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2","volume":"57","author":"Genovese","year":"2018","journal-title":"Rheumatology"},{"key":"2025090312540292000_8.2.e002457.19","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150826"},{"key":"2025090312540292000_8.2.e002457.20","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.180249"},{"key":"2025090312540292000_8.2.e002457.21","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1002\/acr.24046","article-title":"Composite measures of disease activity in psoriatic arthritis: comparative instrument performance based on the efficacy of guselkumab in an interventional phase II trial","volume":"72","author":"Helliwell","year":"2020","journal-title":"Arthritis Care Res"},{"key":"2025090312540292000_8.2.e002457.22","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211998"},{"key":"2025090312540292000_8.2.e002457.23","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1002\/acr.23571","article-title":"Burden of psoriatic arthritis according to different definitions of disease activity: comparing minimal disease activity and the disease activity index for psoriatic arthritis","volume":"70","author":"Wervers","year":"2018","journal-title":"Arthritis Care Res"},{"key":"2025090312540292000_8.2.e002457.24","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2017-eular.3762","article-title":"FRI0498 outcomes associated with achievement of various treatment targets in patients with psoriatic arthritis receiving adalimumab","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025090312540292000_8.2.e002457.25","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214140"},{"key":"2025090312540292000_8.2.e002457.26","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.171034"},{"key":"2025090312540292000_8.2.e002457.27","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001240"},{"key":"2025090312540292000_8.2.e002457.28","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/acr.22401","article-title":"Factors explaining the discrepancy between physician and patient global assessment of joint and skin disease activity in psoriatic arthritis patients","volume":"67","author":"Eder","year":"2015","journal-title":"Arthritis Care Res"},{"key":"2025090312540292000_8.2.e002457.29","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/rheumatology\/keaa271","article-title":"Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis","volume":"60","author":"Coates","year":"2021","journal-title":"Rheumatology"},{"key":"2025090312540292000_8.2.e002457.30","first-page":"14","article-title":"Tofacitinib improves composite endpoint measures of disease in patients with psoriatic arthritis","volume":"48","author":"Helliwell","year":"2018","journal-title":"Internal Medicine"},{"key":"2025090312540292000_8.2.e002457.31","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/acr.22204","article-title":"Comparison of composite measures of disease activity in psoriatic arthritis using data from an interventional study with golimumab","volume":"66","author":"Helliwell","year":"2014","journal-title":"Arthritis Care Res"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2022-002457","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:54:07Z","timestamp":1756929247000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2022-002457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,9,28]]},"published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1136\/rmdopen-2022-002457"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2022-002457","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9]]}}}